These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 9474188)

  • 81. Stromal cell-derived factor-1 and vascular endothelial growth factor as biomarkers for lymph node metastasis and poor cancer-specific survival in prostate cancer patients after radical prostatectomy.
    Wang Q; Diao X; Sun J; Chen Z
    Urol Oncol; 2013 Apr; 31(3):312-7. PubMed ID: 21367627
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Prognostic value of connexin43 expression in patients with clinically localized prostate cancer.
    Benko G; Spajić B; Demirović A; Stimac G; Kru Sbreve Lin B; Tomas D
    Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):90-5. PubMed ID: 21173791
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Elevated Skp2 protein expression in human prostate cancer: association with loss of the cyclin-dependent kinase inhibitor p27 and PTEN and with reduced recurrence-free survival.
    Yang G; Ayala G; De Marzo A; Tian W; Frolov A; Wheeler TM; Thompson TC; Harper JW
    Clin Cancer Res; 2002 Nov; 8(11):3419-26. PubMed ID: 12429629
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Beta-tubulin III expression in prostate cancer.
    Egevad L; Valdman A; Wiklund NP; Sève P; Dumontet C
    Scand J Urol Nephrol; 2010 Dec; 44(6):371-7. PubMed ID: 20831453
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Acquired expression of p27 is a favorable prognostic indicator in patients with hepatocellular carcinoma.
    Fiorentino M; Altimari A; D'Errico A; Cukor B; Barozzi C; Loda M; Grigioni WF
    Clin Cancer Res; 2000 Oct; 6(10):3966-72. PubMed ID: 11051245
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Inducible nitric oxide synthase (iNOS) expression and its prognostic value in prostate cancer.
    Aaltoma SH; Lipponen PK; Kosma VM
    Anticancer Res; 2001; 21(4B):3101-6. PubMed ID: 11712818
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Intensity of stromal changes predicts biochemical recurrence-free survival in prostatic carcinoma.
    Tomas D; Spajić B; Milosević M; Demirović A; Marusić Z; Kruslin B
    Scand J Urol Nephrol; 2010 Nov; 44(5):284-90. PubMed ID: 20459359
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Pathological T2 sub-divisions as a prognostic factor in the biochemical recurrence of prostate cancer.
    Caso JR; Tsivian M; Mouraviev V; Polascik TJ; Moul JW
    BJU Int; 2010 Dec; 106(11):1623-7. PubMed ID: 20553260
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Expression and localization of hypoxia proteins in prostate cancer: prognostic implications after radical prostatectomy.
    Jans J; van Dijk JH; van Schelven S; van der Groep P; Willems SH; Jonges TN; van Diest PJ; Bosch JL
    Urology; 2010 Apr; 75(4):786-92. PubMed ID: 19854473
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer.
    Umbas R; Isaacs WB; Bringuier PP; Schaafsma HE; Karthaus HF; Oosterhof GO; Debruyne FM; Schalken JA
    Cancer Res; 1994 Jul; 54(14):3929-33. PubMed ID: 7518346
    [TBL] [Abstract][Full Text] [Related]  

  • 91. beta-catenin expression and claudin expression pattern as prognostic factors of prostatic cancer progression.
    Szász AM; Nyirády P; Majoros A; Szendrõi A; Szûcs M; Székely E; Tõkés AM; Romics I; Kulka J
    BJU Int; 2010 Mar; 105(5):716-22. PubMed ID: 19818082
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Expression of cell cycle-regulated proteins in prostate cancer.
    Mashal RD; Lester S; Corless C; Richie JP; Chandra R; Propert KJ; Dutta A
    Cancer Res; 1996 Sep; 56(18):4159-63. PubMed ID: 8797586
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Can telomere alterations predict biochemical recurrence in prostate adenocarcinoma? A preliminary study.
    Baydar DE; Ozen H; Geyik PO; Gurel B
    Pathol Res Pract; 2010 Oct; 206(10):700-4. PubMed ID: 20674190
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Cytoplasmic p27 expression is an independent prognostic factor in ovarian cancer.
    Duncan TJ; Al-Attar A; Rolland P; Harper S; Spendlove I; Durrant LG
    Int J Gynecol Pathol; 2010 Jan; 29(1):8-18. PubMed ID: 19952944
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer.
    Minner S; Kraetzig F; Tachezy M; Kilic E; Graefen M; Wilczak W; Bokemeyer C; Huland H; Sauter G; Schlomm T
    Hum Pathol; 2011 Dec; 42(12):1946-52. PubMed ID: 21683980
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Pathological significance and predictive value for biochemical recurrence of c-Fes expression in prostate cancer.
    Miyata Y; Watanabe S; Matsuo T; Hayashi T; Sakai H; Xuan JW; Greer PA; Kanda S
    Prostate; 2012 Feb; 72(2):201-8. PubMed ID: 21563194
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer.
    Halvorsen OJ; Haukaas SA; Akslen LA
    Clin Cancer Res; 2003 Apr; 9(4):1474-9. PubMed ID: 12684422
    [TBL] [Abstract][Full Text] [Related]  

  • 98. N-myc downstream regulated gene-1/Cap43 may play an important role in malignant progression of prostate cancer, in its close association with E-cadherin.
    Song Y; Oda Y; Hori M; Kuroiwa K; Ono M; Hosoi F; Basaki Y; Tokunaga S; Kuwano M; Naito S; Tsuneyoshi M
    Hum Pathol; 2010 Feb; 41(2):214-22. PubMed ID: 19800102
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Expression and prognostic role of syndecan-2 in prostate cancer.
    Popović A; Demirović A; Spajić B; Stimac G; Kruslin B; Tomas D
    Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):78-82. PubMed ID: 19786981
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Increased nuclear factor erythroid 2-related factor 2 expression predicts worse prognosis of prostate cancer patients treated with radical prostatectomy.
    Raatikainen S; Aaltomaa S; Kärjä V; Soini Y
    Hum Pathol; 2014 Nov; 45(11):2211-7. PubMed ID: 25175169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.